MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	MEL- Belvarafeni Cobi 6	JUSO 200mg QD mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
GRyalue -2 -0.5 -0.5 -0.5	GRvalue In the state of the st	GRvalue 1.0 0.5 0.5 0.0 0.0 0.5 0.5	GRvalue	GRvalue 1.0 0.5 0.0 -0.5	GRvalue Who are the state of t	GRvalue 1.0	GRvalue 1.0 0.5 0.0 -0.5	GRvalue -1 - -2 - -3 - -3 -	GRvalue MEXICO DIVIDITION OF THE PROPERTY OF	GRvalue 1.0 0.5 0.5 -0.3	-1 - William William WEKI Cooperation And American Marketing Cooperation And American Andrews	GRvalue 1.0 MRKI Copine fund with a second control of the second	GRvalue 1.0 WEXIVE 0.5 0.0 -0.5 -3	GRvalue	GRvalue 1.0	GRvalue 1.0 0.5 0.0 -0.5
-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 panRAFi_Be MEL- Belvarafenit Cobi 60	varafenib uM USO 200mg QD ng QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess 0.50 0.25 0.00 0.00 0.05 0.05 0.05 0.05	HSA Excess 0.50 0.25 0.25 0.00 -0.25 -0.50	HSA Excess 0.50 0.25 0.00 -0.25 -0.50	HSA Excess 0.50	HSA Excess 0.50 0.25 0.00 -0.25 -0.50	HSA Excess 0.50 Wn -2 - 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00	HSA Excess 0.50 0.50 0.00 -0.25 0.00 -0.25 -0.50	HSA Excess 0.50 0.25 0.00 -0.25 -0.50	HSA Exces 0.50 0.25 0.00 -0.25	HSA Excess 0.50 0.50 0.25 0.00 0.00 -0.25 0.50 -0.50	HSA Excess 0.50 0.25 0.00 -0.26	ess 500 Wn -2 - 25 in its author of the control of	HSA Excess 0.50 Win -2 - 0.25 Unique unique of the control of the	HSA Excess 0.50 WD -2 - 0.25 0.00 -0.25 -0.50 -0.50 -3 -	HSA Excess 0.50 Which is the state of the st	HSA Excess 0.50 0.00 0.00 0.05 -0.25 -0.50 -0.50 -0.50 -0.50 -3	HSA Excess 0.50 0.25 0.00 -0.25 -0.50
-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	_4	rarafenib uM USO 200mg QD ng QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
Bliss Excess 0.50 0.50 0.25 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.5	Bliss Excess 0.50 0.25 0.00 0.00 0.00 0.00 0.00 0.00	Bliss Excess 0.50 0.00	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.	Bliss Excess 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	Bliss Exces 0.50 0.25 0.00 -0.2i	Bliss Excess 0.50 0.50 0.25 0.00 -0.25 -0.50	Bliss Excess 0.50 0.25 0.00 -0.26	esss 50	Bliss Excess 0.50 0.00 -0.25 -0.25 -0.50 -0.50 -3	Bliss Excess 0.50 0.00 -0.25 -0.50 -0.50 -3	Bliss Excess 0.50 0.00 0.00 0.00 -0.25 -0.50 -3	Bliss Excess 0.50 0.00 0.00 -0.25 -0.50 -0.50 -3 -	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50
panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	panRAFi_Be SK-I Belvarafeni Cobi 6	earafenib uM EL-2 200mg QD mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 60mg QD
GRvalue 1.0 0.5 0.0 -0.5	GRvalue John digital and the second	GRvalue 1.0 0.5 0.5 0.0 0.0 NAW	GRvalue 1.0 Wn quinting 1.0 Wn quinti	GRvalue 1.0 0.5 0.0 -0.5	GRyalue Job	GRvalue 1.0 9.5 0.0 Name of the control of the	GRvalue 1.0 0.5 0.0 -0.5	GRvalue 1.0 0.5 -0.	GRyalue GRyalue GRyalue Job 1.0 Job	GRvalue 1.0 0.5 0.0 -0.1	2.0. What is a second of the s	GRvalue 1.0 WEXITO DISTRIBUTION 0.5 -0.5 -3	GRvalue 1.0 Wn -2 - 0.5 Liqoy -0.5 -3 -	GRvalue 1.0	GRvalue 1.0	GRvalue 1.0 0.5 0.0 -0.5
SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 200mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	SK-MEL-2 Belvarafenib 200mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	SK-N Belvarafenik Cobi 60	EL-2 200mg QD ng QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess -2 - 0.5 -0.5 -0.5	HSA Excess Win quiun qui quo o o o o o o o o o o o o o o o o o o	HSA Excess Wn quintend properties of the second properties of the seco	HSA Excess Wn quiuipeuigoOT)yaW -2 - 0.5	HSA Excess -0.5 -0.5 -0.5	HSA Excess Win quitable and the second secon	HSA Excess Win quiting of the control of the contr	HSA Excess	HSA Exces HSA Exces 0.5 0.0	HSA Excess HSA Excess 0.5 0.0 0.0 -0.5	HSA Excess 0.5 0.0 -0.5	2-1 - 5	HSA Excess 0.5 0.0 -0.5 -0.5 -0.5 -3-	HSA Excess Wn -2 - 0.5 0.0 -0.5 -3 -	HSA Excess Wn -2 - 0.5	HSA Excess Win qui au di proprio de la companya de	HSA Excess 0.5 0.0 -0.5
panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	-4 -3 panRAFi_Be SK-N Belvarafenib	rarafenib uM EL-2 200mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID
Bliss Excess 0.5 0.0 -0.5	Bliss Excess Was gripped and the state of t	Bliss Excess O.5 O.0 O.0 O.7 Name of the second of the se	Bliss Excess Wn quipuniquo O J.	Bliss Excess 0.5 0.0 -0.5 panRAFi_Belvarafenib uM	Cobi 20mg QD The second secon	Bliss Excess Who captured the second state of	Bliss Excess 0.5 0.0 -0.5 Page 14 A Pag	Bliss Exces -3 panRAFi_Belvarafenib uM	Bliss Excess 5 0.5 0.5 0.5 0.7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Bliss Excess 0.5 0.0 0.0 1.3 panRAFi_Belvarafenib uM	WE WE Copy and the state of the	Bliss Excess 0.5 0.0 0.0 10 10 10 10 10 10 10 10 10 10 10 10 10	Bliss Excess W1 -2 0.5 0.0 -0.5 W3 -2 -3 panRAFi_Belvarafenib uM	Bliss Excess Wn -2 - 0.5	Bliss Excess White the state of the state o	Bliss Excess 0.5 0.0 -0.5 panRAFi_Belvarafenib uM
Cobi 20mg QD Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QD Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 40mg QD	Cobi 40mg QD	Cobi 40mg QD	Cobi 40mg QD	Cobi 60mg QD	Cobi 60mg QD	Beivarareni Cobi 6	200mg QD mg QD	Cobi 60mg QD
GRvalue 1.0 0.5 0.0 -0.5	GRvalue Joseph Graph GRvalue Joseph Graph Joseph Graph	GRvalue 1.0 0.5 0.0 0.0 -0.5	Win quitineuridoo Jiyaw -3 GRvalue Win quitineuridoo Jiyaw -0.5 -0.5 -0.5 -0.5 -0.5	GRvalue 1.0 0.5 0.0 -0.5	GRValue Win Qiuingia ming Qiungia ming Qiuingia ming Qiungia ming	GRvalue 1.0	GRvalue 1.0 0.5 0.0 -0.5	GRvalue 1.0 0.5 0.0 -0.	GRvalue Jos Jos Jos Jos Jos Jos Jos Jo	GRvalue 1.0 0.5 0.0 -0.1	2.0. Who dimension of the control of	GRvalue 1.0 0.5 0.0 -0.5 -3 -4 -4 -3 -2	GRvalue 1.0	GRvalue 1.0 N= 1.0	GRvalue 1.0	GRvalue 1.0 0.5 0.0 -0.5
panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 60mg QD	panRAFi_Be SK-M Belvarafenit Cobi 60	varafenib uM EL-30 200mg QD mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess 0.50 0.25 0.00 0.00 0.00 0.050	HSA Excess 0.50 0.50 0.00 0.00 0.00 0.00 0.05 0.50	HSA Excess 0.50 0.50 0.25 0.00 0.00 0.00 0.00 0.050 0.	HSA Excess	HSA Excess 0.50 0.50 0.25 0.00 -0.25 -0.50	HSA Excess 0.50 wn -2 - 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00	HSA Excess 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.	HSA Excess 0.50 0.25 0.00 -0.25 -0.50	HSA Exces 0.50 0.25 0.00 -0.25 -0.50	HSA Excess 0.50 0.25 0.25 0.00 0.00 -0.25 0.50 -0.50	HSA Excess 0.50 0.25 0.00 0.00 0.00 0.05 0.05 0.05	PSS 50 Who Capacity and Capacit	HSA Excess 0.50 0.00 0.00 -0.25 -0.50 -0.50 -3 -4 -3 -2	HSA Excess 0.50 0.00 -0.25 -0.50 -0.50 -3 -3 -3 -2	HSA Excess 0.50 0.00 0.00 0.00 -0.25 -0.50 -3 -4 -4 -3	HSA Excess 0.50	HSA Excess 0.50 0.25 0.00 -0.25 -0.50
panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg QD Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 60mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 60mg QD	panRAFi_Be SK-M Belvarafenik Cobi 60	aratenib uM EL–30 200mg QD ng QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 60mg QD
Bliss Excess 0.50 0.25 0.00 0.00 0.00 0.00 0.00 0.00	Bliss Excess 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.	Bliss Excess 0.50 0.25 0.00 0.25 0.00 0.25 0.00 0.00	Bliss Excess 0.50	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50 Page 14 -4 -3 -3 -2 -2	Bliss Excess 0.50 0.00 0.00 0.7 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00	Bliss Excess 0.50 0.50 0.00 0.7 0.25 0.00 0.00 0.25 0.00 0.00 0.25 0.00 0.00	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	Bliss Exces 0.50 0.25 0.20 -0.2i	Bliss Excess 0.50 0.50 0.25 0.25 0.50 0.50 0.50 0.50	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50	25 Hand 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Bliss Excess 0.50 0.00 0.00 0.05 -0.25 -0.50 -0.	Bliss Excess 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.	Bliss Excess 0.50 0.00 0.00 0.00 -0.25 -0.50 -3	Bliss Excess 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.	Bliss Excess 0.50 0.25 0.00 -0.25 -0.50